5-HYDROXYTRYPTAMINE RECEPTOR 2B

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 12:03:50 UTC 2023` Edited by `admin` on `Sat Dec 16 12:03:50 UTC 2023`
Protein Type	RECEPTOR
Protein Sub Type	HYDROXYTRYPTAMINE RECEPTOR
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	6E2Z4UWILI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

5-HYDROXYTRYPTAMINE RECEPTOR 2B

Common Name

English

5-HT2B

Common Name

English

5HT2B

Common Name

English

Code System Code Type Description

UNIPROT

P41595

Created by admin on Sat Dec 16 12:03:52 UTC 2023 , Edited by admin on Sat Dec 16 12:03:52 UTC 2023

PRIMARY

FDA UNII

6E2Z4UWILI

Created by admin on Sat Dec 16 12:03:52 UTC 2023 , Edited by admin on Sat Dec 16 12:03:52 UTC 2023

PRIMARY

From	To
1_128	1_207
1_350	1_353

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_30

Related Record Type Details


					NK36K7QB8G

A-372159

PARTIAL AGONIST->TARGET

Amount:


					5ASJ6HUZ7D

DOXEPIN

INHIBITOR -> TARGET

Amount:


					32CN2DQE3Q

25CN-NBOH

AGONIST -> TARGET

Amount:


					TUK9RFW5YL

ORG-12962

AGONIST -> TARGET

Amount:


					366ZW99DGL

BF-1

INHIBITOR -> TARGET

Qualification:

Amount:


					9SK6K682UL

DOET

PARTIAL AGONIST->TARGET

Amount:


					2Z9TC7YMY4

LY-266097

INHIBITOR -> TARGET

Amount:


					E35R3G56OV

DEXFENFLURAMINE

AGONIST->OFF-TARGET

Comments:

5-HT2B receptors, which were subsequently identified as the target for cardiac valvulopathy and pulmonary hypertension. Release of serotonin leads to 5-HT2B signaling.

Amount:


					637E494O0Z

LORCASERIN

WEAK AGONIST->OFF TARGET

Qualification:

Amount:


					R1KWM2Z2QN

MBL C-11

RADIOLIGAND->TARGET

Qualification:

Amount:


					22QOO9B8KI

ELETRIPTAN

AGONIST -> TARGET

Comments:

Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors

Amount:


					M7FHF24Q22

SDZ SER-082

INHIBITOR -> TARGET

Comments:

Acts as a mixed antagonist for the 5-HT2B and 5-HT2C serotonin receptors, with good selectivity over other serotonin receptor subtypes and slight preference for 5-HT2C over 5-HT2B.

Interaction Type:

ANTAGONIST


					285VE60914

6-APB

AGONIST -> TARGET

Comments:

A full agonist.

Qualification:

Amount:


					X8L60BA01I

BRILAROXAZINE

INHIBITOR -> TARGET

Amount:


					3VMW6141KC

5-METHOXYTRYPTAMINE

AGONIST -> TARGET

Interaction Type:

BINDING

Qualification:

IC50

Amount:


					5NV3JP3GP6

LY-272015 hydrochloride

INHIBITOR -> TARGET

Interaction Type:

ANTAGONIST

Amount:


					J7HPJ854EA

PNU-22394

PARTIAL AGONIST->TARGET


					82SK298EBU

PRX-08066 FREE BASE

INHIBITOR -> TARGET

Qualification:

Amount:


					OOM10GW9UE

DOI

INHIBITOR -> TARGET

Interaction Type:

BINDING

Qualification:

IC50

Amount:


					0JAU3P8OBM

RS-127445

INHIBITOR -> TARGET

Amount:


					RT8F72CL8L

SB-200646

INHIBITOR -> TARGET

Interaction Type:

ANTAGONIST

Amount:


					65MKC68UST

1-METHYLPSILOCIN

INVERSE AGONIST->TARGET

Qualification:

IC50

Amount:


					8JMH6M2ELN

BW-723C86

AGONIST -> TARGET

Interaction Type:

BINDING

Qualification:

IC50

Amount:


					82VFR53I78

ARIPIPRAZOLE

INVERSE AGONIST->TARGET

Qualification:

Amount:


					F6RJL8B278

CARIPRAZINE

INHIBITOR -> TARGET

Qualification:

Amount:


					DV8DX4568D

CORYDALMINE, (-)-

INHIBITOR -> TARGET

Amount:


					ODG984O60W

NORFENFLURAMINE, (R)-

AGONIST -> TARGET

Qualification:

Amount:


					48QQ8ZTE6C

ORG-37684 Free Base

AGONIST -> TARGET

Amount:


					KT54N4CC67

AL-37350A

AGONIST -> TARGET


					Y48NWN4BHC

R-167154

INHIBITOR -> TARGET

Amount:


					4R5ZNV2CHC

ST-1936

AGONIST -> TARGET


					MN9LW8268N

WAY-163909

WEAK AGONIST->OFF TARGET

Comments:

Emax,40%

Amount:


					76NY5U584E

AL-38022A

AGONIST -> TARGET

Amount:


					137R1N49AD

AGOMELATINE

INHIBITOR -> TARGET

Amount:


					2DS058H2CF

FENFLURAMINE

AGONIST->OFF-TARGET

Comments:

5-HT2B receptors, which were subsequently identified as the target for cardiac valvulopathy and pulmonary hypertension. Release of serotonin leads to 5-HT2B signaling.

Amount:


					N7U69T4SZR

OLANZAPINE

INHIBITOR -> TARGET

Amount:


					SCG2HM6F3D

WAY-161503

AGONIST -> TARGET

Amount:


					J4CZH8D9EN

6-FLUORO-DMT

AGONIST -> TARGET

Amount:


					8NA5SWF92O

LYSERGIDE

AGONIST -> TARGET

Qualification:

Amount:


					99VKK4S5SA

RQ-00310941

INHIBITOR -> TARGET

Qualification:

Amount:


					8Z68P5BWL7

DOI I-125

RADIOLIGAND->TARGET

Qualification:

Amount:


					9VHM49MS42

SB-204741

INHIBITOR -> TARGET

Interaction Type:

ANTAGONIST

Amount:


					CLX07A6ZIY

NORDEXFENFLURAMINE

AGONIST->OFF-TARGET

Comments:

Responsible for valvular heart disease (VHD) with the administration of phentermine and fenfluramine (phen/fen) and dexfenfluramine1 led to the withdrawal of fenfluramine and dexfenfluramine from the marketplace in September 1997.

Qualification:

Amount:


					037A9J3PSW

NORFENFLURAMINE

AGONIST->OFF-TARGET

Comments:

We propose that preferential stimulation of valvular 5-HT2B receptors by norfenfluramine, ergot drugs, or 5-HT released from carcinoid tumors (with or without accompanying 5-HT2A receptor activation) may contribute to valvular fibroplasia in humans.

Qualification:

Amount:


					2M3825704H

5-APB

AGONIST->OFF-TARGET

Comments:

Indeed all drugs and drug metabolites that induce heart valvular disease in humans activate 5-HT2B receptors in vivo and in vitro and this activity is thought to be important for the development of fibrotic lesions upon chronic human administration.

Qualification:

Amount:


					CLX07A6ZIY

NORDEXFENFLURAMINE

AGONIST -> TARGET

Qualification:

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT	CHEMICAL